Recent Updates in Liver Failure (2024-2026)

1. Definitions and Classification - Refined

Acute Liver Failure (ALF)

Acute-on-Chronic Liver Failure (ACLF) - Major 2025 Update

• Profound anorexia, persistent vomiting, abdominal distension
• Markedly elevated ALT/AST with progressive hyperbilirubinemia (TBil 5-12 mg/dL)
• Progressive coagulopathy (PTA declining, INR <1.5)

2. Pathophysiology - Updated Understanding

• ALF encephalopathy is driven by cerebral edema (not portosystemic shunting)
• ACLF encephalopathy involves both cerebral edema and portosystemic shunting
• Rapid hepatocyte loss causes massive cytokine release → tissue hypoxia + lactic acidosis
• Factor V remains the most sensitive biomarker (shortest half-life among clotting factors) for trend monitoring

3. Prognostic Scoring - Updates

• CLIF-C ACLF score and MELD/MELD-Na remain core tools
• New evidence (2025 meta-analysis, PMID 41025046) confirms that presence of underlying cirrhosis independently worsens prognosis in ACLF patients
• Sarcopenia is now a validated prognostic factor: a 2025 meta-analysis (PMID 40287653) shows sarcopenic ACLF patients have significantly higher short-term mortality

4. Management Updates

4a. General ICU Stabilization (ALF)

• Stabilize in ICU; address neurologic, respiratory, hemodynamic, infectious, and renal complications
• N-acetylcysteine (NAC): Loading 140 mg/kg then 70 mg/kg every 4 hours
  • Firmly indicated in acetaminophen toxicity
  • Also commonly given in idiosyncratic DILI, acute hepatitis B, autoimmune hepatitis, and indeterminate ALF (especially grade 1-2 encephalopathy), based on limited but supportive data
• Cause-specific therapy: nucleos(t)ide analogues (acute HBV), acyclovir (HSV), copper chelation (Wilson's disease)

4b. Nutrition (2025 ACLF Guidelines)

• Grade ≤2 hepatic encephalopathy (HE): Maintain protein intake 1.2-1.5 g/kg/day, with incremental increases using fractionated feeding
• Grade ≥3 HE: Temporarily reduce protein; use branched-chain amino acid (BCAA) formulations; use post-pyloric tube to prevent aspiration; initiate parenteral nutrition if oral/enteral routes are contraindicated

4c. Haemostasis - Updated Approach (2025)

• Both ALF and ACLF show a rebalanced coagulation state (not simply bleeding prone)
• Routine prophylactic FFP or platelet transfusion is NOT supported for non-bleeding patients
• Viscoelastic testing (TEG/ROTEM) is preferred over standard INR for assessing true bleeding risk

4d. Extracorporeal Liver Support (ECLS) - Significant New Evidence

• 1-month mortality OR: 0.63 (95% CI 0.51-0.76)
• 3-month mortality OR: 0.70 (95% CI 0.61-0.81)
• Reduced rates of HE, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS)
• Patients with lower MELD scores and lower bilirubin benefit most

4e. Therapeutic Plasma Exchange (PLEX) - Now Supported by Meta-Analysis

• 30-day mortality reduction: RR 0.70 (95% CI 0.60-0.81, p<0.001)
• 90-day mortality reduction: RR 0.81 (95% CI 0.77-0.86, p<0.001)
• 1-year survival benefit: RR 0.85 (95% CI 0.79-0.92, p<0.0001)
• Benefit seen in HBV-related AND alcohol-related ACLF
• Main adverse effects: skin rash and allergic reactions (~14%)

4f. Acute Kidney Injury in ACLF - New APASL Guidelines (2024)

• Early identification using serum creatinine trends (not just absolute values)
• Volume resuscitation with albumin as first-line
• Avoiding nephrotoxic drugs; terlipressin for HRS-AKI where available

5. Liver Transplantation - Updated Criteria

• Liver transplantation improves prognosis across ALL grades of ACLF, including Grade 3 (previously considered prohibitive)
• Survival benefit is significant even in the sickest patients, challenging older notions of ACLF grade 3 as a contraindication
• AASLD-AST published new practice guidelines on liver transplant candidate evaluation (December 2025) and post-transplant management (March 2026)

6. Emerging/Future Therapies

• Stem cell therapy: A 2025 systematic review (PMID 41266258) shows immunomodulatory benefits of stem cells in liver fibrosis/failure contexts, though still investigational
• Anti-inflammatory agents: Ongoing trials targeting the inflammatory cascade in ACLF
• Microbiome modulation: Rifaximin and fecal microbiota transplant under active investigation for gut-liver axis in ACLF
• G-CSF therapy: Still under evaluation; mixed results across different populations

Summary Table: Key 2024-2026 Updates